Vascular Endothelial Growth Factor (VEGF) induces angiogenesis, but also disrupts vascular barrier function in diseased tissues. VEGF-mediated pathogenic effects are due to its effects on vascular permeability, resulting in injury to ischemic tissues after stroke or myocardial infarction. In cancer, VEGF-mediated disruption of the vascular barrier may lead to metastatic disease.
VEGF can reliably be measured with a novel
Human VEGF ELISA assay
utilizing epitope-mapped recombinant antibodies enabling a highly sensitive and specific quantification of VEGF in various sample types.